The trademark application ULSYMMBI was filed by Bristol-Myers Squibb Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on September 17, 2023, and it was registered by office on December 25, 2023 without any oppositions.
The application was filed in English (Italian was selected as the second language).
Change of name and professional address of the trademark registration was recorded on January 11, 2024.